Analgesic treatment and predictors of satisfaction with analgesia in patients with acute undifferentiated abdominal pain.

The objectives of this prospective, observational cohort study were to examine current practice of analgesia in adults with acute abdominal pain presenting to emergency department (ED), to assess patient-physician agreement on pain severity, and to measure patients' satisfaction with pain management. METHODS: Emergency room nurse assessed initial patient's and physician's ranking on a 0-100mm visual analogue scale (VAS) as well as patient's VAS rankings 5min, 15min, and 60min after starting treatment for pain, and on discharge. In patients who received no therapy VAS scores were assessed 5min, 15min, and 60min after initial examination, and on discharge. Patient's satisfaction with pain management on discharge from ED was assessed using a four-point categorical scale in which 1=completely unsatisfied, 2=mostly unsatisfied, 3=mostly satisfied, and 4=completely satisfied. RESULTS: A total of 185 patients were enrolled. Patients' mean initial VAS was higher than physicians' (76+/-20mm, vs. 59+/-20mm, p<0.001). Physician's VAS > or = 60mm was the sole independent predictor of receiving analgesic therapy (p<0.001). On discharge from ED, 111 patients (60%) were predominantly satisfied with analgesia (satisfaction score > or = 3). Drug titration (p=0.026) and decrease in VAS score > or = 20mm between initial and discharge score (p<0.001) independently predicted patients' satisfaction. CONCLUSIONS: Patients with acute abdominal pain rated pain significantly higher than physicians who's pain estimation in turn tailored analgesia. Only 60% of patients were satisfied with analgesia. Analgesic drug titration and a decrease of > or = 20mm on VAS predicted patients' satisfaction.     

Pulmonary alveolar microlithiasis in childhood: clinical and radiological follow-up

This report describes a case of pulmonary alveolar microlithiasis that was diagnosed in an 8.5-year-old girl by high-resolution computed tomography (CT) and open lung biopsy. Presence of symptoms (productive cough, fever), their periodic occurrence (lasting up to 1 week), and comparatively long asymptomatic periods should be emphasized. Despite extensive X-ray abnormalities, tests of pulmonary interstitium involvement and exercise tests revealed normal results. A therapeutic regimen, including disodium etidronate, was administered for 18 months with no significant clinical or radiological improvement.     

Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma

Multiple myeloma (MM) is a hematological malignancy characterized by the aberrant accumulation of clonal plasma cells in the bone marrow. Despite recent advancement in anti-myeloma treatment, MM remains an incurable disease. This study showed higher intrinsic oxidative stress and higher Trx1 and TrxR1 protein levels in MM cells compared to normal cells. Drug-induced Trx1 (PX-12) and TrxR1 (Auranofin) inhibition disrupted redox homeostasis resulting in ROS-induced apoptosis in MM cells and a reduction in clonogenic activity. Knockdown of either Trx1 or TrxR1 reduced MM cell viability. Trx1 inhibition by PX-12 sensitized MM cells to undergo apoptosis in response to the NF-кβ inhibitors, BAY 11-7082 and curcumin. PX-12 treatment decreased the expression of the NF-кβ subunit p65 in MM cells. Bortezomib-resistant MM cells contained higher Trx1 protein levels compared to the parental cells and PX-12 treatment resulted in apoptosis. Thus, increased Trx1 enhances MM cell growth and survival and exerts resistance to NF-кβ inhibitors. Therefore inhibiting the thioredoxin system may be an effective therapeutic strategy to treat newly diagnosed as well as relapsed/refractory MM.